Natco Pharma
Natco Pharma Limited, headquartered in Hyderabad, India, is a prominent player in the pharmaceutical industry, specialising in the development, manufacturing, and marketing of generic and specialty medicines. Founded in 1981, the company has achieved significant milestones, including the launch of several high-quality generic formulations and active pharmaceutical ingredients (APIs) that cater to various therapeutic areas such as oncology, cardiology, and neurology. With a strong presence in both domestic and international markets, Natco Pharma is recognised for its commitment to innovation and affordability. The company’s core products, including complex generics and biosimilars, stand out due to their quality and accessibility. Natco's strategic focus on research and development has positioned it as a leader in the pharmaceutical sector, earning accolades for its contributions to healthcare and patient well-being.
DitchCarbon Score
How does Natco Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Natco Pharma's score of 31 is higher than 57% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Natco Pharma's reported carbon emissions
In 2024, Natco Pharma reported total carbon emissions of approximately 28,403,250 kg CO2e for Scope 1 and about 41,763,620 kg CO2e for Scope 2. This marks a slight decrease from 2023, where emissions were approximately 31,342,070 kg CO2e for Scope 1 and about 39,945,230 kg CO2e for Scope 2. Over the past three years, the company has shown a commitment to reducing its carbon footprint, with emissions in 2022 recorded at about 13,477,000 kg CO2e for Scope 1 and approximately 44,967,000 kg CO2e for Scope 2. Natco Pharma has set ambitious targets to enhance renewable energy (RE) in its energy mix, aiming for a 35% increase by the end of 2035. This commitment applies to both Scope 1 and Scope 2 emissions, reflecting the company's strategy to transition towards more sustainable energy sources. The company has not disclosed any Scope 3 emissions data, indicating a potential area for future reporting and improvement. Overall, Natco Pharma's climate commitments demonstrate a proactive approach to managing its carbon emissions and contributing to global sustainability efforts.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | 13,265,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 44,696,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Natco Pharma is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
